Fig. 6.
Route of vaccine administration dictates the antitumor effects of peptide vaccines. CD45.1 WT-B6 mice were inoculated s.c. with 3 × 105 B16F10 melanoma cells and 7 days later, when tumors were measurable the mice received 10,000 TnTR1 CTLs followed by 2 doses of pam-Trp1/TriVax administered i.v, i.m or s.c. a Mean tumor sizes in each group (n = 10 mice). b Percentages of TnTR1 CTLs in blood from (a) at day 25. c Similar experiment as in (a), but comparing the antitumor effects of pam-Trp1/TriVax and LP-Trp1/TriVax administered either i.v. or s.c. (n = 10 mice). Results in (b) are presented as individual mice (each symbol) with the mean ± SD for each group. These experiments were repeated 2–3 times with similar results